9 METERS BIOPHARMA, INC.

2021 Q4 Form 10-Q Financial Statement

#000155198621000118 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.99M $53.61M $12.44M
YoY Change 24.16% 330.94% 40.41%
Cash & Equivalents $46.99M $53.61M $12.44M
Short-Term Investments
Other Short-Term Assets $2.992M $2.870M $1.200M
YoY Change 177.03% 139.17% 39.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $49.99M $56.48M $13.63M
YoY Change 28.41% 314.27% 40.26%
LONG-TERM ASSETS
Property, Plant & Equipment $16.09K $16.38K $44.97K
YoY Change 43.81% -63.57% 57.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.580K $5.580K $5.580K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $188.3K $201.2K $276.5K
YoY Change -18.68% -27.24% 206.1%
TOTAL ASSETS
Total Short-Term Assets $49.99M $56.48M $13.63M
Total Long-Term Assets $188.3K $201.2K $276.5K
Total Assets $50.17M $56.68M $13.91M
YoY Change 28.13% 307.49% 41.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.434M $1.316M $2.565M
YoY Change 63.61% -48.67% -16.11%
Accrued Expenses $5.968M $5.911M $6.067M
YoY Change 12.81% -2.57% 225.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $1.270M
YoY Change -100.0% -100.0% -67.27%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.457M $7.281M $10.11M
YoY Change 23.49% -27.97% -22.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $113.1K $127.5K $180.0K
YoY Change -33.45% -29.19%
Total Long-Term Liabilities $113.1K $127.5K $180.0K
YoY Change -33.45% -29.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.457M $7.281M $10.11M
Total Long-Term Liabilities $113.1K $127.5K $180.0K
Total Liabilities $8.570M $7.408M $10.29M
YoY Change 22.15% -28.0% -21.64%
SHAREHOLDERS EQUITY
Retained Earnings -$168.8M -$159.3M -$127.1M
YoY Change 27.85% 25.32% 106.13%
Common Stock $25.82K $25.55K $14.96K
YoY Change 26.2% 70.82% 316.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $41.60M $49.27M $3.621M
YoY Change
Total Liabilities & Shareholders Equity $50.17M $56.68M $13.91M
YoY Change 28.13% 307.49% 41.79%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001551986
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37797
dei Entity Registrant Name
EntityRegistrantName
9 METERS BIOPHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3948465
dei Entity Address Address Line1
EntityAddressAddressLine1
8480 Honeycutt Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 120
dei Entity Address City Or Town
EntityAddressCityOrTown
Raleigh
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27615
dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
dei City Area Code
CityAreaCode
919
dei Local Phone Number
LocalPhoneNumber
275-1933
dei Security12b Title
Security12bTitle
Common Stock $0.0001 Par Value
dei Trading Symbol
TradingSymbol
NMTR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
255667567 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53608585 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37851388 USD
CY2021Q3 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
0 USD
CY2020Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
75000 USD
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
859187 USD
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
691929 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2010838 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
308658 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
56478610 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
38926975 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16382 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11191 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
179205 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
214767 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2021Q3 us-gaap Assets
Assets
56679777 USD
CY2020Q4 us-gaap Assets
Assets
39158513 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1316381 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1487948 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5911454 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5290181 USD
CY2021Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 USD
CY2020Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
14216 USD
CY2021Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
7000 USD
CY2021Q3 us-gaap Interest Payable Current
InterestPayableCurrent
0 USD
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
488 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
53185 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
48629 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7281020 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6848462 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
127460 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
167938 USD
CY2021Q3 us-gaap Liabilities
Liabilities
7408480 USD
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2020Q4 us-gaap Liabilities
Liabilities
7016400 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
255531751 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
255531751 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
204629064 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
204629064 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
25553 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
20463 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
208531431 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
164182917 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159285687 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132061267 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
49271297 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
32142113 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56679777 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39158513 USD
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6049444 USD
CY2020Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4413707 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
14947036 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7457509 USD
CY2021Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5103753 USD
CY2020Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5103753 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
32266893 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2386461 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1890492 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7146432 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9220020 USD
CY2021Q3 nmtr Warrant Inducement Expense
WarrantInducementExpense
0 USD
CY2020Q3 nmtr Warrant Inducement Expense
WarrantInducementExpense
0 USD
nmtr Warrant Inducement Expense
WarrantInducementExpense
0 USD
nmtr Warrant Inducement Expense
WarrantInducementExpense
7157887 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
13539658 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
6304199 USD
us-gaap Operating Expenses
OperatingExpenses
27197221 USD
us-gaap Operating Expenses
OperatingExpenses
56102309 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13539658 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6304199 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-27197221 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-56102309 USD
CY2021Q3 us-gaap Interest Income Other
InterestIncomeOther
1397 USD
CY2020Q3 us-gaap Interest Income Other
InterestIncomeOther
3295 USD
us-gaap Interest Income Other
InterestIncomeOther
12989 USD
us-gaap Interest Income Other
InterestIncomeOther
24660 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
1970 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
2118433 USD
us-gaap Interest Expense
InterestExpense
47188 USD
us-gaap Interest Expense
InterestExpense
3710725 USD
CY2021Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
CY2020Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
86000 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
7000 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
617000 USD
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2637500 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-573 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2029138 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27199 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-431565 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13540231 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8333337 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27224420 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-56533874 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-13540231 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8333337 USD
us-gaap Net Income Loss
NetIncomeLoss
-27224420 USD
us-gaap Net Income Loss
NetIncomeLoss
-56533874 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
254284692 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
254284692 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
141625796 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
141625796 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
238530148 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
238530148 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87323241 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87323241 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
32142113 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
422000 USD
CY2021Q1 nmtr Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
6857028 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75903 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5431079 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
34065965 USD
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34500000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2901123 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
937000 USD
CY2021Q2 nmtr Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
668439 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
120739 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8253110 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
59137910 USD
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2718587 USD
CY2021Q3 nmtr Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
399967 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30064 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
525000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-13540231 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
49271297 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-9614014 USD
CY2020Q1 nmtr Stock Issued During Period Value Warrant Exchange
StockIssuedDuringPeriodValueWarrantExchange
690839 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
276000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
300000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3603001 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-12550176 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
28754026 USD
CY2020Q2 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
22560994 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3589703 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4021000 USD
CY2020Q2 nmtr Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
1219001 USD
CY2020Q2 nmtr Adjustments To Additional Paid In Capital Warrant Inducement Expense
AdjustmentsToAdditionalPaidInCapitalWarrantInducementExpense
6467048 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
575000 USD
CY2020Q2 nmtr Convertible Promissory Notes Beneficial Conversion Feature
ConvertiblePromissoryNotesBeneficialConversionFeature
-207632 USD
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-44597536 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
3067286 USD
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2459583 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
73149 USD
CY2020Q3 nmtr Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
826987 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
3567977 USD
CY2020Q3 nmtr Convertible Promissory Notes Beneficial Conversion Feature
ConvertiblePromissoryNotesBeneficialConversionFeature
-1903228 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
202000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8333337 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
3620575 USD
us-gaap Net Income Loss
NetIncomeLoss
-27224420 USD
us-gaap Net Income Loss
NetIncomeLoss
-56533874 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1884000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4499000 USD
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
0 USD
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
298048 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
43983 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1288098 USD
nmtr Convertible Promissory Notes Beneficial Conversion Feature
ConvertiblePromissoryNotesBeneficialConversionFeature
0 USD
nmtr Convertible Promissory Notes Beneficial Conversion Feature
ConvertiblePromissoryNotesBeneficialConversionFeature
2110860 USD
us-gaap Depreciation
Depreciation
4657 USD
us-gaap Depreciation
Depreciation
16883 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-7031 USD
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-7000 USD
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-617000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2637500 USD
nmtr Warrant Inducement Expense
WarrantInducementExpense
0 USD
nmtr Warrant Inducement Expense
WarrantInducementExpense
7157887 USD
nmtr Asset Acquisition Research And Development In Process
AssetAcquisitionResearchAndDevelopmentInProcess
2610588 USD
nmtr Asset Acquisition Research And Development In Process
AssetAcquisitionResearchAndDevelopmentInProcess
28754026 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1869438 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
498873 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-63567 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1388457 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3114077 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4549153 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-488 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
3427 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21507608 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12991291 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9848 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2543 USD
us-gaap Increase Decrease Of Restricted Investments
IncreaseDecreaseOfRestrictedInvestments
-75000 USD
us-gaap Increase Decrease Of Restricted Investments
IncreaseDecreaseOfRestrictedInvestments
0 USD
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
2493165 USD
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3184454 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2428013 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3186997 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2500000 USD
us-gaap Repayments Of Debt
RepaymentsOfDebt
58199 USD
us-gaap Repayments Of Debt
RepaymentsOfDebt
1469804 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
23000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
226706 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34500000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2370012 USD
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
0 USD
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
22560994 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2901123 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3962852 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7925434 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2045988 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
39692818 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24021338 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15757197 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7843050 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37851388 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4592932 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53608585 USD
CY2020Q2 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
22600000 USD
CY2020Q2 nmtr Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants Net
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsNet
19200000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12435982 USD
us-gaap Interest Paid Net
InterestPaidNet
569 USD
us-gaap Interest Paid Net
InterestPaidNet
54578 USD
nmtr Noncash Addition Of Derivative Liability
NoncashAdditionOfDerivativeLiability
0 USD
nmtr Noncash Addition Of Derivative Liability
NoncashAdditionOfDerivativeLiability
370000 USD
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
ReclassificationsCertain prior period amounts have been reclassified to conform to current period presentation. These changes had no effect on previously reported net loss, financial position or cash flows.
CY2020Q4 nmtr Sale Of Stock Shelf Registration Maximum Equity Offering Price
SaleOfStockShelfRegistrationMaximumEquityOfferingPrice
200000000 USD
CY2019Q4 nmtr Class Of Warrant Or Right Number Of Shares Issued Per Warrant
ClassOfWarrantOrRightNumberOfSharesIssuedPerWarrant
1.2 shares
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
12230418 shares
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.10
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1200000 USD
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.10
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
137130 USD
us-gaap Use Of Estimates
UseOfEstimates
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include accrued expenses, share-based compensation, valuation of the derivative liability and warrant liabilities, valuation allowance for income tax assets, and management’s assessment of the Company’s ability to continue as a going concern. The Company considered the impact of the COVID-19 pandemic on its estimates and assumptions, and concluded there was not a material impact to its condensed consolidated financial statements as of and for the three and nine months ended September 30, 2021. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</span></div>
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1203218 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1111028 USD
CY2021Q3 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4571106 USD
CY2020Q4 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4042277 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
136876 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5911454 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5290181 USD
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
7000 USD
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 USD
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
0 USD
CY2021Q3 nmtr Warrants Accumulated Gross Unrealized Gain
WarrantsAccumulatedGrossUnrealizedGain
7000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2600000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
46300000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
46300000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
57100000 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
57100000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
46305829 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
57114096 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2020Q2 nmtr Number Of Amended And Restated License Agreements
NumberOfAmendedAndRestatedLicenseAgreements
2 license_agreement
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53600000 USD
CY2021Q3 nmtr Milestone Payment
MilestonePayment
500000 USD
nmtr Accrued Milestone Fees
AccruedMilestoneFees
500000 USD
CY2021Q3 nmtr Accrued Milestone Fees
AccruedMilestoneFees
500000 USD
nmtr Accrued Milestone Fees
AccruedMilestoneFees
2200000 USD
CY2020Q3 nmtr Accrued Milestone Fees
AccruedMilestoneFees
2200000 USD
CY2021Q2 nmtr Capital Stock Authorized
CapitalStockAuthorized
560000000 shares
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
600000 shares
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 nmtr Convertible Preferred Stock Beneficial Conversion Feature
ConvertiblePreferredStockBeneficialConversionFeature
3100000 USD
CY2020Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
12500000 USD
CY2020Q2 nmtr Preferred Stock Warrant Value
PreferredStockWarrantValue
7000000 USD
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
255531751 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
204629064 shares
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
52121283 shares
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
66167171 shares
CY2019Q4 nmtr Class Of Warrant Or Right Number Of Shares Issued Per Warrant
ClassOfWarrantOrRightNumberOfSharesIssuedPerWarrant
1.2 shares
nmtr Stock Issued During Period Shares Exercise Of Warrants
StockIssuedDuringPeriodSharesExerciseOfWarrants
1847309 shares
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
12230418 shares
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1200000 USD
CY2021Q3 nmtr Number Of Stock Option Plans
NumberOfStockOptionPlans
2 plan
CY2021Q2 nmtr Sale Of Stock Extended Option Period
SaleOfStockExtendedOptionPeriod
P12M
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4499000 USD
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
525000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
202000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1884000 USD
nmtr Severance Provisions Annual Base Salary Period
SeveranceProvisionsAnnualBaseSalaryPeriod
P12M
nmtr Severance Provisions Continuation Of Health Insurance Benefits Period
SeveranceProvisionsContinuationOfHealthInsuranceBenefitsPeriod
P12M
us-gaap Severance Costs1
SeveranceCosts1
0 USD
CY2020Q3 us-gaap Severance Costs1
SeveranceCosts1
0 USD
CY2021Q3 us-gaap Severance Costs1
SeveranceCosts1
0 USD
us-gaap Severance Costs1
SeveranceCosts1
800000 USD
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2020Q3 nmtr Operating Lease Annual Rental Payments
OperatingLeaseAnnualRentalPayments
72000 USD
CY2020Q3 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
6000 USD
CY2020Q3 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
6000 USD
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
233206 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
233206 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
18000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
54000 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
17880 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
47880 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
100000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
18000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
72000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
72000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
54000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
216000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
35355 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
180645 USD

Files In Submission

Name View Source Status
0001551986-21-000118-index-headers.html Edgar Link pending
0001551986-21-000118-index.html Edgar Link pending
0001551986-21-000118.txt Edgar Link pending
0001551986-21-000118-xbrl.zip Edgar Link pending
ex-21assetpurchaseagrmt.htm Edgar Link pending
ex311q32021.htm Edgar Link pending
ex312q32021.htm Edgar Link pending
ex321q32021.htm Edgar Link pending
ex322q32021.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nmtr-20210930.htm Edgar Link pending
nmtr-20210930.xsd Edgar Link pending
nmtr-20210930_cal.xml Edgar Link unprocessable
nmtr-20210930_def.xml Edgar Link unprocessable
nmtr-20210930_g1.jpg Edgar Link pending
nmtr-20210930_htm.xml Edgar Link completed
nmtr-20210930_lab.xml Edgar Link unprocessable
nmtr-20210930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending